Pacira BioSciences Inc. has entered into a new Credit Agreement with Wells Fargo Bank, National Association, and other lenders as of July 3, 2025. This agreement involves a senior secured revolving credit facility with a commitment amount of $300 million, aimed at refinancing Pacira's previous term loan A facility and providing ongoing working capital. The facility, which matures on July 3, 2030, includes a $10 million letter of credit sublimit and a $15 million swingline loan sublimit, secured by the assets of the company and its subsidiaries. The new arrangement allows for potential expansion through incremental term facilities. Notably, Pacira terminated its existing credit agreement without incurring prepayment penalties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.